Inherited Polyneuropathies

PM and R

Volumn 5, Issue 5 SUPPL., 2013, Pages

  Rinaldi, Robert ^a   Patel, Atul ^b  

^a CHILDREN S MERCY HOSPITAL   (United States)

^b Kansas City Bone and Joint Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; BIOLOGICAL MARKER; GANGLIOSIDE INDUCED DIFFERENTIATION ASSOCIATED PROTEIN 1; GAP JUNCTION B1 PROTEIN; GAP JUNCTION PROTEIN; GLYCINE TRANSFER RNA LIGASE; IB KINASE COMPLEX ASSOCIATED PROTEIN; MYELIN PROTEIN; MYOTUBULARIN RELATED PROTEIN 2; NERVE GROWTH FACTOR; NEUROFILAMENT LIGHT CHAIN PROTEIN; NEUROFILAMENT PROTEIN; PROTEIN TYROSINE KINASE A; RAB PROTEIN; SERINE PLAMITOYLTRANSFERASE LONG CHAIN BASE 1; SET BINDING PROTEIN 2; TRANSIENT RECEPTOR POTENTIAL CHANNEL 4; UNCLASSIFIED DRUG;

ARTICLE; ATAXIA; CLINICAL FEATURE; DEMYELINATION; ELECTROPHYSIOLOGY; GENETIC SCREENING; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; INHERITED NEUROPATHY; MUSCLE ATROPHY; MUSCLE WEAKNESS; PHENOTYPE; POLYNEUROPATHY; PRIORITY JOURNAL; SCOLIOSIS;

DIAGNOSIS, DIFFERENTIAL; ELECTRODIAGNOSIS; HEREDITARY SENSORY AND AUTONOMIC NEUROPATHIES; HEREDITARY SENSORY AND MOTOR NEUROPATHY; HUMANS; NEUROLOGIC EXAMINATION;

EID: 84878117784     PISSN: 19341482     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pmrj.2013.03.028     Document Type: Article

References (23)

1. Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth's disease. Clin Genet 1974, 6:98-118.
2. Inherited Peripheral Neuropathies Mutation Database University of Antwerp, Updated February 17, 2011. Accessed October 1, 2012. http://www.Molgen.ua.ac.be/CMTMutations.
3. Klein C.J. The inherited neuropathies. Neurol Clin 2007, 25:173-207.
4. Saporta A., Sottile S.L., Miller L., Feely S., Siskind C.E., Shy M.E. Charcot-Marie-Tooth disease subtypes and genetic testing strategies. Ann Neurol 2011, 69:22-33.
5. Harding A.E., Thomas P.K. The clinical features of hereditary and sensory neuropathy types I and II. Brain 1980, 103:259-280.
6. Krampitz D.E., Wolfe G.I., Fleckenstein J.L., Barohn R.J. Charcot-Marie-Tooth type 1A presenting as calf hypertrophy and muscle cramps. Neurology 1998, 51:1508-1509.
7. Barisic N., Claeys K.G., Sirotkovic-Skerlev M., et al. Charcot-Marie-Tooth disease: A clinico-genetic confrontation. Ann Hum Genet 2008, 72:416-441.
8. Amato A.A., Russell J.A. Neuromuscular Disorders 2008, McGraw-Hill, New York, NY.
9. Hahn A.F., Brown W.F., Koopman W.F., Feasby T.E. X-linked dominant hereditary motor and sensory neuropathy. Brain 1990, 113:1511-1525.
10. Kawakami H., Inoue K., Sakakihara I., Nakamura S. Novel mutation in X-linked Charcot-Marie-Tooth disease associated with CNS impairment. Neurology 2002, 59:923-926.
11. Panas M., Kalfakis N., Karadimas C., et al. Episodes of generalized weakness in two sibs with the C164T mutation of the Connexin 32 gene. Neurology 2001, 57:1906-1908.
12. Siskind C.E., Shy M.E. Genetics of neuropathies. Semin Neurol 2011, 31:494-505.
13. GeneTests Medical Genetics Information Resource University of Washington, Published 1993. Updated March 22, 2012. Accessed October 1, 2012. http://www.Genetests.org.
14. Dubourg O., Tardieu S., Birouk N., et al. The frequency of 17p11.2 duplication and Connexin 32 mutations in 282 Charcot-Marie-Tooth families in relation to the mode of inheritance and motor nerve conduction velocity. Neuromuscul Disord 2001, 11:458-463.
15. England J.D., Gronseth G.S., Franklin G., et al. Practice parameter: The evaluation of distal symmetric polyneuropathy: The role of laboratory and genetic testing (an evidence based review). Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. PM R 2009, 1:5-13.
16. Burgunder J.M., Schols L., Baets J., et al. EFNS guidelines for the molecular diagnosis of neurogenetic disorders: Motoneuron, peripheral nerve and muscle disorders. Eur J Neurol 2011, 18:207-217.
17. England J.D., Gronseth G.S., Franklin G., et al. Practice parameter: The evaluation of distal symmetric polyneuropathy: The role of autonomic testing, nerve biopsy, and skin biopsy. Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. PM R 2009, 1:14-22.
18. Bromberg M.B. Review of the evolution of electrodiagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2011, 43:780-794.
19. Stanton M., Pannoni V., Lewis R.A., et al. Dispersion of compound action potential in hereditary neuropathies and chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2006, 34:417-422.
20. Nicolas G., Maisonobe T., Le Forestier N., Léger J.M., Bouche P. Proposed revised electrophysiological criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2002, 25:26-30.
21. Murray N., Wade D. The sural sensory action potential in Guilain-Barre syndrome. Muscle Nerve 1980, 3:444.
22. Bromberg M., Albers J. Patterns of nerve conduction abnormalities in demyelinating and axonal peripheral nerve disorders. Muscle Nerve 1993, 16:262-266.
23. Rajabally Y.A., Narasimhan M. The value of sensory electrophysiology in chronic inflammatory demyelinating polyneuropathy. Clin Neurophysiol 2007, 118:1999-2004.